Peer-reviewed veterinary case report
Effectiveness of resveratrol and allopurinol for treating canine
By Erdogan, Songul et al.·Published in Journal of the American Veterinary Medical Association·2025·Faculty of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative clinical efficiency of resveratrol, allopurinol, and resveratrol plus allopurinol in canine visceral leishmaniasis.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with canine visceral leishmaniasis (CVL) were treated with either resveratrol, allopurinol, or a combination of both to see which worked best. The dogs receiving both medications showed the most improvement, with significant reductions in symptoms and antibody levels. Those on allopurinol alone also improved, but not as much as the combination group. Resveratrol by itself helped too, but less effectively than when paired with allopurinol. This suggests that using both treatments together could be a better option for dogs suffering from CVL.
People also search for: dog leishmaniasis treatment · resveratrol for dogs · allopurinol for canine leishmaniasis
Abstract
OBJECTIVE: To assess the clinical and immunological effectiveness of resveratrol alone or combined with allopurinol for treating canine visceral leishmaniasis (CVL). METHODS: This study included 50 dogs, 30 diagnosed with CVL and 20 healthy controls. Dogs were classified based on their treatment regime (receiving resveratrol [200 mg/dog/d] and/or allopurinol [10 mg/kg/d]). Clinical scores, anti-leishmanial antibody titers, and routine blood parameters were evaluated on days 0, 15, and 30 after treatment. RESULTS: Dogs treated with the combination therapy showed the most substantial improvements, with a 75.77% reduction in clinical scores and an 81.25% reduction in antibody titers. Dogs receiving allopurinol exhibited a 56.25% reduction in clinical scores, while those treated with resveratrol showed a 42.82% reduction. Antibody titers were less significantly reduced in the resveratrol group (67.5%) compared to the allopurinol group (45%). CONCLUSIONS: Combining resveratrol with allopurinol enhances the therapeutic efficacy for CVL, leading to significant clinical improvements and reductions in antibody titers. Resveratrol alone also demonstrates promising anti-leishmanial effects. CLINICAL RELEVANCE: Resveratrol, either alone or in combination with allopurinol, offers a feasible and effective alternative for improving clinical outcomes in CVL. Its incorporation into standard protocols may enhance treatment strategies in veterinary medicine.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39938209/